Related Experiment Videos
CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity
A M Camoratto1, J P Jani, T S Angeles
1Cephalon, Inc., West Chester, PA 19380, USA. acamorat@cephalon.com
Abstract:
The present report describes the in vitro and in vivo profile of CEP-751, a novel receptor tyrosine kinase inhibitor. CEP-751 at 100 nM inhibits the receptor tyrosine kinase activity of the neurotrophin receptors trkA, trkB and trkC. CEP-751 has no effect on activity of receptors for EGF, IGF-I, insulin or on erbB2; inhibition of receptors for PDGF and bFGF was observed but occurred with lesser potency than inhibition of trk. CEP-751 exhibited anti-tumor efficacy against tumors derived from NIH3T3 cells transfected with trkA. Inhibition of trk phosphorylation could also be measured in these tumors, suggesting that anti-tumor efficacy of CEP-751 is related to inhibition of trk receptor tyrosine kinase activity. CEP-751 was found to be without effect when administered to nude mice bearing SK-OV-3 tumors, which overexpress erbB2 receptors, providing further evidence that inhibition of tumor growth may be related to inhibition of trk receptor tyrosine kinase activity. Our data indicate that CEP-751 is a potent trk inhibitor which possesses anti-tumor activity.
Insights
CEP-751 is a novel receptor tyrosine kinase inhibitor that effectively targets neurotrophin receptors trkA, trkB, and trkC. This inhibitor demonstrates significant anti-tumor efficacy against trkA-driven tumors, suggesting its potential in cancer therapy.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Receptor tyrosine kinases (RTKs) play crucial roles in cell signaling and are often dysregulated in cancer.
- Targeting specific RTKs offers a promising strategy for cancer therapy.
Purpose of the Study:
- To characterize the in vitro and in vivo profile of CEP-751, a novel RTK inhibitor.
- To evaluate the anti-tumor efficacy of CEP-751 and its mechanism of action.
Main Methods:
- In vitro kinase assays to assess inhibition of various RTKs.
- In vivo studies using tumor models in nude mice.
- Measurement of trk phosphorylation in tumor tissues.
Main Results:
- CEP-751 potently inhibits the tyrosine kinase activity of neurotrophin receptors trkA, trkB, and trkC at 100 nM.
- CEP-751 demonstrated anti-tumor efficacy against NIH3T3-derived tumors transfected with trkA.
- Inhibition of trk phosphorylation correlated with anti-tumor activity.
- CEP-751 showed no effect on tumors overexpressing erbB2, further supporting trk-specific activity.
Conclusions:
- CEP-751 is a potent inhibitor of trk receptor tyrosine kinase activity.
- CEP-751 exhibits anti-tumor activity, likely mediated through the inhibition of trk signaling.
- These findings suggest CEP-751 as a potential therapeutic agent for trk-dependent tumors.